Jennifer S Read1,2, Brenda Torres-Velasquez1, Olga Lorenzi1, Aidsa Rivera Sanchez1, Sanet Torres-Torres3, Lillian V Rivera3,4, Sheila M Capre-Franceschi3, Carlos Garcia-Gubern5, Jorge Munoz-Jordan1, Gilberto A Santiago1, Luisa I Alvarado3. 1. Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Diseases, Office of Infectious Diseases, Centers for Disease Control and Prevention, San Juan, Puerto Rico. 2. Now with Department of Pediatrics, University of Vermont Medical Center, Burlington. 3. Department of Pediatrics, St Luke's Episcopal Hospital-Ponce Health Sciences University Consortium, Ponce, Puerto Rico. 4. Department of Pediatrics, School of Medicine, Ponce Health Sciences University School of Medicine, Ponce, Puerto Rico. 5. Department of Emergency Medicine, St. Luke's Episcopal Hospital-Ponce Health Sciences University Consortium, Ponce, Puerto Rico.
Abstract
Importance: Little information is available regarding Zika virus (ZIKV) infection in children. Objective: To describe patients younger than 18 years who were infected with ZIKV and were enrolled in the Sentinel Enhanced Dengue and Acute Febrile Illness Surveillance System (SEDSS). Design, Setting, and Participants: Children infected with ZIKV with 7 or fewer days of fever or emancipated minors aged 14 to 17 years with a generalized maculopapular rash, arthritis or arthralgia, or nonpurulent conjunctivitis were eligible for enrollment on or before December 31, 2016, in Puerto Rico. Patients were evaluated using ZIKV polymerase chain reaction testing at 7 or fewer days after the onset of symptoms. Available ZIKV polymerase chain reaction-positive specimens were evaluated to determine viral loads. Exposures: Confirmed polymerase chain reaction-positive ZIKV infection. Main Outcomes and Measures: Clinical characteristics and viral loads of symptomatic children with confirmed ZIKV infection. Results: Of 7191 children enrolled in SEDSS on or before December 31, 2016, only those with confirmed ZIKV infection (351 participants) were included in this study. Participants who had confirmed ZIKV infection included 25 infants (7.1%), 69 children (19.7%) aged 1 to 4 years, 95 (27.1%) aged 5 to 9 years, and 162 (46.1%) aged 10 to 17 years. Among these, 260 patients (74.1%) presented for evaluation of ZIKV infection at fewer than 3 days after the onset of symptoms, 340 (96.9%) were discharged to home after evaluation, and 349 (99.4%) had fever, 280 (79.8%) had a rash, 243 (69.2%) had facial or neck erythema, 234 (66.7%) had fatigue, 223 (63.5%) had headache, 212 (60.4%) had chills, 206 (58.7%) had pruritus, and 204 (58.1%) had conjunctival hyperemia. Of 480 specimens collected (317 serum and 163 urine specimens) from 349 children, the median number of days after the onset of symptoms was lower for children who had serum specimens (1 day [interquartile range (IQR), 1-2 days]) than for children who had urine specimens (2 [1-3] days) (P < .001). Of 131 children who had both serum and urine specimens collected on the same day, the median viral load was higher in serum than in urine (median [IQR], 23 098 [8784-88 242] copies/mL for serum vs 9966 [2815-52 774] copies/mL for urine; P = .02). When a single serum sample from each of 317 patients was analyzed, there were no statistically significant differences in median viral loads according to age, sex, or disposition. However, the median serum viral load varied significantly according to the number of days after the onset of symptoms (0 days, 106 778 [IQR, 9772-1 571 718] copies/mL; 1 day, 46 299 [10 663-255 030] copies/mL; 2 days, 20 678 [8763-42 458] copies/mL; and ≥3 days, 15 901 [5135-49 248] copies/mL; P = .001). Conclusions and Relevance: This study represents the largest study to date of ZIKV infection in the pediatric population. Most children infected with ZIKV had fever, rash, and conjunctival hyperemia. The children usually presented for evaluation at fewer than 3 days after the onset of symptoms. Viral loads for ZIKV were higher in serum vs urine specimens. Median viral loads in serum specimens differed significantly according to the number of days after the onset of symptoms.
Importance: Little information is available regarding Zika virus (ZIKV) infection in children. Objective: To describe patients younger than 18 years who were infected with ZIKV and were enrolled in the Sentinel Enhanced Dengue and Acute Febrile Illness Surveillance System (SEDSS). Design, Setting, and Participants: Children infected with ZIKV with 7 or fewer days of fever or emancipated minors aged 14 to 17 years with a generalized maculopapular rash, arthritis or arthralgia, or nonpurulent conjunctivitis were eligible for enrollment on or before December 31, 2016, in Puerto Rico. Patients were evaluated using ZIKV polymerase chain reaction testing at 7 or fewer days after the onset of symptoms. Available ZIKV polymerase chain reaction-positive specimens were evaluated to determine viral loads. Exposures: Confirmed polymerase chain reaction-positive ZIKV infection. Main Outcomes and Measures: Clinical characteristics and viral loads of symptomatic children with confirmed ZIKV infection. Results: Of 7191 children enrolled in SEDSS on or before December 31, 2016, only those with confirmed ZIKV infection (351 participants) were included in this study. Participants who had confirmed ZIKV infection included 25 infants (7.1%), 69 children (19.7%) aged 1 to 4 years, 95 (27.1%) aged 5 to 9 years, and 162 (46.1%) aged 10 to 17 years. Among these, 260 patients (74.1%) presented for evaluation of ZIKV infection at fewer than 3 days after the onset of symptoms, 340 (96.9%) were discharged to home after evaluation, and 349 (99.4%) had fever, 280 (79.8%) had a rash, 243 (69.2%) had facial or neck erythema, 234 (66.7%) had fatigue, 223 (63.5%) had headache, 212 (60.4%) had chills, 206 (58.7%) had pruritus, and 204 (58.1%) had conjunctival hyperemia. Of 480 specimens collected (317 serum and 163 urine specimens) from 349 children, the median number of days after the onset of symptoms was lower for children who had serum specimens (1 day [interquartile range (IQR), 1-2 days]) than for children who had urine specimens (2 [1-3] days) (P < .001). Of 131 children who had both serum and urine specimens collected on the same day, the median viral load was higher in serum than in urine (median [IQR], 23 098 [8784-88 242] copies/mL for serum vs 9966 [2815-52 774] copies/mL for urine; P = .02). When a single serum sample from each of 317 patients was analyzed, there were no statistically significant differences in median viral loads according to age, sex, or disposition. However, the median serum viral load varied significantly according to the number of days after the onset of symptoms (0 days, 106 778 [IQR, 9772-1 571 718] copies/mL; 1 day, 46 299 [10 663-255 030] copies/mL; 2 days, 20 678 [8763-42 458] copies/mL; and ≥3 days, 15 901 [5135-49 248] copies/mL; P = .001). Conclusions and Relevance: This study represents the largest study to date of ZIKV infection in the pediatric population. Most children infected with ZIKV had fever, rash, and conjunctival hyperemia. The children usually presented for evaluation at fewer than 3 days after the onset of symptoms. Viral loads for ZIKV were higher in serum vs urine specimens. Median viral loads in serum specimens differed significantly according to the number of days after the onset of symptoms.
Authors: Iara J F Motta; Bryan R Spencer; Suely G Cordeiro da Silva; Monica B Arruda; Jane A Dobbin; Yung B M Gonzaga; Ingrid P Arcuri; Rita C B S Tavares; Elias H Atta; Regina F M Fernandes; Deise A Costa; Liane J Ribeiro; Fabio Limonte; Luiza M Higa; Carolina M Voloch; Rodrigo M Brindeiro; Amilcar Tanuri; Orlando C Ferreira Journal: N Engl J Med Date: 2016-08-17 Impact factor: 91.245
Authors: Roosecelis Brasil Martines; Julu Bhatnagar; Ana Maria de Oliveira Ramos; Helaine Pompeia Freire Davi; Silvia D'Andretta Iglezias; Cristina Takami Kanamura; M Kelly Keating; Gillian Hale; Luciana Silva-Flannery; Atis Muehlenbachs; Jana Ritter; Joy Gary; Dominique Rollin; Cynthia S Goldsmith; Sarah Reagan-Steiner; Yokabed Ermias; Tadaki Suzuki; Kleber G Luz; Wanderson Kleber de Oliveira; Robert Lanciotti; Amy Lambert; Wun-Ju Shieh; Sherif R Zaki Journal: Lancet Date: 2016-06-29 Impact factor: 79.321
Authors: José R Sotelo; Andre B Sotelo; Fabio J B Sotelo; André M Doi; Joao R R Pinho; Rita de Cassia Oliveira; Alanna M P S Bezerra; Alice D Deutsch; Lucy S Villas-Boas; Alvina C Felix; Camila M Romano; Clarisse M Machado; Maria C J Mendes-Correa; Rubia A F Santana; Fernando G Menezes; Cristovao L P Mangueira Journal: Emerg Infect Dis Date: 2017-05-15 Impact factor: 6.883
Authors: Patrícia Brasil; Guilherme Amaral Calvet; André Machado Siqueira; Mayumi Wakimoto; Patrícia Carvalho de Sequeira; Aline Nobre; Marcel de Souza Borges Quintana; Marco Cesar Lima de Mendonça; Otilia Lupi; Rogerio Valls de Souza; Carolina Romero; Heruza Zogbi; Clarisse da Silveira Bressan; Simone Sampaio Alves; Ricardo Lourenço-de-Oliveira; Rita Maria Ribeiro Nogueira; Marilia Sá Carvalho; Ana Maria Bispo de Filippis; Thomas Jaenisch Journal: PLoS Negl Trop Dis Date: 2016-04-12
Authors: Nicholas J Maness; Blake Schouest; Anil Singapuri; Maria Dennis; Margaret H Gilbert; Rudolf P Bohm; Faith Schiro; Pyone P Aye; Kate Baker; Koen K A Van Rompay; Andrew A Lackner; Myrna C Bonaldo; Robert V Blair; Sallie R Permar; Lark L Coffey; Antonito T Panganiban; Diogo Magnani Journal: Sci Rep Date: 2019-09-05 Impact factor: 4.996
Authors: Robert A Kozak; Lee W Goneau; Cedric DeLima; Olivia Varsaneux; AliReza Eshaghi; Erik Kristjanson; Romy Olsha; David Safronetz; Stephen Perusini; Christine Frantz; Jonathan B Gubbay Journal: Viruses Date: 2020-01-24 Impact factor: 5.048
Authors: Liliana Sánchez-González; Chelsea G Major; Dania M Rodriguez; Abirami Balajee; Kyle R Ryff; Olga Lorenzi; Mariely Linares; Laura E Adams; Vanessa Rivera-Amill; Melissa Rolfes; Gabriela Paz-Bailey Journal: Am J Trop Med Hyg Date: 2022-07-11 Impact factor: 3.707
Authors: Franciane Mouradian Emidio Teixeira; Anna Julia Pietrobon; Luana de Mendonça Oliveira; Luanda Mara da Silva Oliveira; Maria Notomi Sato Journal: Front Immunol Date: 2020-02-14 Impact factor: 7.561
Authors: Simon Pollett; Caitlin H Kuklis; David A Barvir; Richard G Jarman; Rachel M Romaine; Brett M Forshey; Gregory D Gromowski Journal: PLoS Negl Trop Dis Date: 2022-01-21